MADISON Pfizer Inc., a major biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, nonprofit patenting and licensing organization for the University of Wisconsin-Madison, announced May 5 that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.
The WARF license provides Pfizer the rights to work with hES cells for drug research and discovery. Securing appropriate licenses, in an area as broad and rapidly moving as regenerative medicine, helps ensure rapid and efficient utilization of the many existing discoveries and inventions in this field and allows for the efficient transfer of information for development of future inventions.
"Our license with WARF provides us with information and materials that will allow us to use their cell lines to explore a whole new range of therapies," says Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine. "Stem cells can be used to create specialized human tissue. Our scientists will determine how new medicines may be able to improve the way stem cells regenerate damaged tissues. We will be optimizing the production of cells that could, one day, be used for therapeutic purposes."
"Pfizer's stem-cell R&D goal is three fold: to use human cells as tools in our drug discovery efforts, to improve the safety of new treatments and, most importantly, to move towards cell therapy," says McKernan. "The benefit to public health could be tremendous as we pursue our discoveries to advance the treatment of debilitating diseases."
"We are pleased to enter into this licensing agreement with Pfizer," said Carl E. Gulbrandsen, managing director of WARF. "Pfizer's access to this key intellectual property may have far-reaching benefits for both public health and Wisconsin's growing biotechnology industry."
As advances in health care help people live longer, the need for new medicines
'/>"/>
| Contact: Janet Kelly jkelly@warf.org 608-890-1491 University of Wisconsin-Madison Source:Eurekalert |
Related biology news :
1. Unifying the animate and the inanimate designs of nature
2. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
3. UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity
4. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
5. Engineering technology pinpoints earliest signs of animal life
6. University of Miami engineer designs stretchable electronics with a twist
7. bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC
8. Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimers disease
9. Great Ape Trust signs agreement with Universitas Nasional in Jakarta
10. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |